Innovation Pharmaceuticals Inc (IPIX)

[cabel]

Reading the following it's hard to imagine Purisol Phase 2b NOT achieving spectacular results!



Looking at the Phase 2a trial we had 28 patients in the 200mg arm.

Of the 28 patients 9 were Mild and 18 were Moderate psoriasis patients.

For the 200mg (28) arm and for Moderate (18) Psoriasis patients only,... 46% of those patients had a 2 point reduction using the IGA scale which translates roughly to PASI90. True not alot of patients in the study but still 46% 18 patients!

Otezla had 8% PASI90,...

If we simply repeat the results of Phase 2a,... we get 46% PASI90

Things that are happening in Phase 2a that might increase that number for us:

1) we are now dosing at 300mg and 400mg

2) we are now dosing patients with Moderate/Severe Psoriasis instead of Mild/Moderate in Phase 2a. It is a given that Mod/Sev patients respond better than Mild/Mod.

Looking at Phase 2B we see we will have 27 patients dosing at 400mg,... twice the dosage of Phase 2a where we got 46% PASI90 using 18 patients!

It is possible that we might double the results

Imagine 90% PASI90,... stock price would open pat $10,.. deal or no deal.

And we know that Prurisol is dose dependant and that there is little liklyhood of adverse side effects as it has been tested for safety up to 600-800mg

We will also have 81 patients dosing at 300mg (50% higher than Phase 2a),... so if we follow with an equal percentage gain of 50%,..

That could translate to 70% PASI90 in a very strong statistical study!